Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex
- 17 October 1989
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 28 (21), 8317-8326
- https://doi.org/10.1021/bi00447a009
Abstract
Interaction of von Willebrand factor (vWF) with its platelet receptor only occurs in vitro in the presence of a modula such as ristocetin. We have recently confirmed that the human platelet membrane glycoprotein (GP) Ib-IX complex is the receptor involved in the ristocetin-dependent binding of vWF by reconstitution with the purified components [Berndt, M. C., Du, X., and Booth, W. J. (1988) Biochemistry 27, 633-640]. We have now developed a similar solid-phase reconstitution assay using an alternate modulator, botrocetin, for the competitive analysis of functional domains in both vWF and the GP Ib-IX complex. Botrocetin was purified from Bothrops jararaca venom by ammonium sulfate fractionation and subsequent DEAE-cellulose and hydroxylapatite chromatography. The purified protein was a 25-kilodalton (kDa) disulfide-linked dimer with apparent subunit molecular weights of 14,000 and 14,500. Binding studies with immobilized botrocetin demonstrated that botrocetin bound to vWF and to a 52/48-kDa region of vWF that contains that GP Ib binding domain, but not to glycocalicin, a proteolytic fragment of GP Ib that contains the vWF binding site. Binding of 125I-labeled vWF to GP Ib-IX complex coated beads and to platelets was strictly botrocetin-dependent with half-maximal binding at a botrocetin concentration of .simeq. 0.27 .mu.M. Botrocetin-dependent binding of vWF was specific, saturable, and comparable to that observed with ristocetin. An anti-vWF monoclonal antibody, 3F8, inhibited ristocetin- but not botrocetin-dependent binding to vWF, suggesting the presence of distinct ristocetin and botrocetin modulator sites on vWF. The botrocetin reconstitution assay was at least an order of magnitude more sensitive than the corresponding ristocetin assay for the competitive analysis of functional domains on both vWF and the GP Ib-IX complex and has confirmed the localization of the vWF-binding domain to the 45-kDa N-terminal region of GP Ib.Keywords
This publication has 38 references indexed in Scilit:
- Studies on the Mechanism of Ristocetin-induced Platelet Aggregation: Binding of Factor VIII to PlateletsBritish Journal of Haematology, 1979
- Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.Journal of Clinical Investigation, 1979
- STUDIES ON THE MECHANISM OF RISTOCETIN-INDUCED PLATELET AGGLUTINATION - BINDING OF RISTOCETIN TO PLATELETS1979
- Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.Proceedings of the National Academy of Sciences, 1978
- The Effects of Ristocetin and von Willebrand Factor on Platelet Electrophoretic MobilityJournal of Clinical Investigation, 1978
- Studies on the Mechanism of Ristocetin-Induced Platelet AgglutinationJournal of Clinical Investigation, 1977
- Dysfibrinogenemia Associated with Liver DiseaseJournal of Clinical Investigation, 1977
- On the interaction between ristocetin and the ristocetin cofactor (RCOF)Thrombosis Research, 1977
- Platelet glycocalicin: A single receptor for platelet aggregation induced by thrombin or ristocetinThrombosis Research, 1976
- A Protein SequenatorEuropean Journal of Biochemistry, 1967